Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
r
eports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight
    Who will benefit most from huge opportunities in NASH treatment? The first new NASH therapy is due soon: but is it safe and effective enough? How happy are KOLs with the plethora of current trials and endpoints? Which...
  • Breast Cancer: KOL Insight
    Learn More Breast Cancer: KOL Insight
    Targeted therapies deliver on promise to transform breast cancer treatment Targeted therapies continue to transform breast cancer treatment—branching out into new settings, targeting new patient populations, and...
  • COPD: KOL Insight
    Learn More COPD: KOL Insight
    Latest Update This edition presents key opinion leader (KOL) views on recent developments in the COPD market. Topics covered include; Novartis’ December 2016 publication of positive results from the CRYSTAL study,...
  • Dyslipidaemia: KOL Insight
    Learn More Dyslipidaemia: KOL Insight
    Effective but expensive: will PCSK9 inhibitors find widespread use in cardiology? PCSK9 inhibitors could be game changers for dyslipidaemia patients. But high cost and long-term safety questions have relegated them to...
  • Head and Neck Squamous Cell Carcinoma: KOL Insight
    Learn More Head and Neck Squamous Cell Carcinoma: KOL Insight
    Immunotherapies are about to transform HNSCC treatment. Can one brand corner the market? Key opinion leaders (KOLs) say immunotherapies will transform the head and neck squamous cell carcinoma (HNSCC) landscape. But until...
  • Rheumatoid Arthritis: KOL Insight
    Learn More Rheumatoid Arthritis: KOL Insight
    Latest Update Gain new KOL insights on the latest events happening in rheumatoid arthritis (RA). During September 2016, the US FDA approved Amgen's Amjevita (adalimumab-atto), as a biosimilar to AbbVie's Humira for...
  • Targeted Therapies In Asthma: KOL Insight
    Learn More Targeted Therapies In Asthma: KOL Insight
    Competition heating up as developers struggle to differentiate pipeline asthma antibodies Innovative monoclonal antibodies are breathing new life into the treatment of severe asthma. But with many of them targeting...
  • Biosimilars in Oncology: KOL Insight
    Learn More Biosimilars in Oncology: KOL Insight
    Will physicians ever adopt Biosimilars in Oncology? Sceptical, survival focussed oncologists that make treatment decisions in life or death situations aren't yet ready to accept biosimilars of proven targeted treatments...
  • Ulcerative Colitis: KOL Insight
    Learn More Ulcerative Colitis: KOL Insight
    Pipeline drugs are poised to reshape the way doctors treat ulcerative colitis (UC). But where will new therapies fit into the UC treatment paradigm? How will they affect existing brands? And what will it all mean for...
  • Prostate Cancer: KOL Insight
    Learn More Prostate Cancer: KOL Insight
    The last decade has seen significant change in how prostate cancer is treated. Innovation and lifecycle management have each played a role in shaping today’s treatment paradigm. But how will results from landmark...
  • Malignant Melanoma: KOL Insight
    Learn More Malignant Melanoma: KOL Insight
    Malignant Melanoma: KOL Insight reveals the impact of immunotherapy on first-line treatment combination choices The arrival of cancer immunotherapy in 2011 significantly changed the landscape for drugs used by...
  • Cancer Immunotherapy: Payer Insight
    Learn More Cancer Immunotherapy: Payer Insight
    Immunotherapies are some of the most promising new weapons in the fight against cancer. But are they promising enough to justify their sky-high prices? Payers aren’t convinced, and say they need better data to make...
  • Multiple Sclerosis: KOL Insight
    Learn More Multiple Sclerosis: KOL Insight
    Roche’s/Biogen’s novel ocrelizumab is set to radically alter the Multiple Sclerosis (MS) treatment paradigm. Which companies and products will lose market share as its use widens and what clinical benefits...
  • Non-Small Cell Lung Cancer: KOL Insight
    Learn More Non-Small Cell Lung Cancer: KOL Insight
    The rapidly evolving non-small cell lung cancer (NSCLC) treatment algorithm is becoming increasingly complex and fragmented. Every advancement brings a new set of questions and concerns. This comprehensive report...
  • Type 2 Diabetes Mellitus: KOL Insight
    Learn More Type 2 Diabetes Mellitus: KOL Insight
    The market for Type 2 Diabetes therapies is extremely crowded. Several classes, including oral and injectable therapies, are all vying for market share. Differentiation remains a critical challenge. What do companies...
  • Psoriasis: KOL Insight (2016)
    Learn More Psoriasis: KOL Insight (2016)
    There is no shortage of effective treatments for psoriasis, and the introduction of novel anti-IL17 and anti-IL23 antibody-based therapies will further expand the treatment options. How will the market develop in the...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved